Core Viewpoint - MicroPort Medical's stock rose over 4% following the announcement of a strategic merger aimed at optimizing resource allocation and enhancing competitiveness in the structural heart disease and rhythm management sectors [1] Group 1: Merger Announcement - MicroPort Medical's independent shareholders approved the merger agreement at a special meeting scheduled for December 15, 2025, with completion expected around December 19, 2025 [1] - The strategic merger is intended to strengthen the synergy between the two companies in the relevant medical fields [1] Group 2: Financial Performance - Citigroup noted that MicroPort Medical's fundamentals are improving, with a 66% year-on-year reduction in net losses for the first half of 2025, and expects the company to achieve profitability in the second half of 2025 [1] - The overseas platform is projected to grow by 70% to 80% year-on-year in 2025, with a continuation of this growth trend into 2026 [1] Group 3: Profit Forecast Adjustments - Everbright Securities anticipates that MicroPort Medical will continue to reduce losses, adjusting the net profit forecast for 2025 and 2026 to -30 million and -96 million USD, respectively, from previous estimates of -59 million and -91 million USD [1]
港股异动 | 微创医疗(00853)涨超4% 花旗料公司25年下半年将录得盈利 此前战略合并将成为上行潜力